lungmap-int-news_0.png

Ryan Hohman, JD, Managing Director, Friends of Cancer Research/ Chair, Lung-MAP Public Affairs Committee: 202.944.6708 or rhohman@focr.org

Wendy Lawton, Communications and Public Relations Manager, SWOG, Lung-MAP Public Affairs Committee: 503.348.8675 or lawtonw@ohsu.edu

Press Releases

Press
29
Jan
2019
Lung-MAP Precision Medicine Trial Expands To Include More Patients

The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI),...

Press
14
Nov
2016
Lung-MAP Infographics Illustrate How the Trial is Helping Patients

 

Press
29
Feb
2016
Lung-MAP Precision Medicine Trial Makes Exciting Changes, With New Science and Treatment Options for Patients

Lung-MAP, the most collaborative and comprehensive lung cancer clinical trial active in the U.S., uses a targeted screening approach to match...

Press
10
Mar
2015
Statement from Lung-MAP Clinical Trial Leadership Regarding FDA Approval of Nivolumab

On March 4, 2015, the U.S. Food and Drug Administration (FDA) announced that it had approved Opdivo (nivolumab) for the treatment of patients with...

Press
03
Dec
2014
Innovative Lung-MAP Lung Cancer Trial Open and Enrolling Patients at over 400 Sites in 39 States

Trial will Close One of Five Trial Sub-Studies: Other four sub-studies of targeted treatments for squamous cell lung cancer will continue to...

Press
06
Nov
2014
“Don’t Guess. Test.” Campaign Aims to Educate Patients About Comprehensive Genomic Testing in Lung Cancer
...
Press
23
Jul
2014
Lung-MAP Collaborative Clinical Trial Rapidly Expanding Across the Country

Groundbreaking study in squamous cell lung cancer opens at more than a hundred and fifty new locations

Press
16
Jun
2014
Groundbreaking Collaborative Clinical Trial Launched

Lung-MAP is a multi-drug, multi-arm, biomarker-driven clinical trial for patients with advanced squamous cell lung cancer.